| Symbol | ALDX |
|---|---|
| Name | ALDEYRA THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 131 HARTWELL AVENUE,SUITE 320, LEXINGTON, Massachusetts, 02421, United States |
| Telephone | +1 781 761-4904 |
| Fax | — |
| — | |
| Website | https://www.aldeyra.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The companys product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Additional info from NASDAQ: |
ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Executive Allegedly Approved Misleading Disclosures: Levi & Korsinsky
Read moreALDX Shareholder Alert: Aldeyra Therapeutics, Inc. Securities Class Action Lawsuit Investors With Losses May Join -- The Gross Law Firm
Read more(99% Neutral) ALDEYRA THERAPEUTICS, INC. (ALDX) Announces New Board Appointment
Read moreAldeyra Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ALDX
Read moreINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aldeyra Therapeutics, Inc. Of Class Action Lawsuit and Upcoming Deadlines - ALDX
Read moreRobbins LLP Encourages ADLX Stockholders Who Lost Money Investing in Aldeyra Therapeutics, Inc. to Contact the Firm for Information About Leading the Class Action
Read moreALDX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Aldeyra Therapeutics, Inc. Securities Lawsuit -- The Gross Law Firm
Read moreAldeyra Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ALDX
Read moreAldeyra Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ALDX
Read moreADLX Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Filed Against Aldeyra Therapeutics, Inc.
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07402876 | A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma | Phase3 | Primary Vitreoretinal Lymphoma | Recruiting | 2026-02-01 | 2026-12-01 | ClinicalTrials.gov |
| NCT06685692 | A Clinical Trial Investigating the Safety and Efficacy of Subjects With Alcohol… | Phase2 | Alcohol Hepatitis | Completed | 2024-11-04 | 2025-06-18 | ClinicalTrials.gov |
| NCT06493604 | A Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease | Phase3 | Dry Eye Disease | Completed | 2024-06-24 | 2025-02-27 | ClinicalTrials.gov |
| NCT06389214 | A Clinical Trial to Assess the Efficacy and Safety of Subjects With Dry Eye Dis… | Phase3 | Dry Eye Disease | Completed | 2024-04-09 | 2024-06-11 | ClinicalTrials.gov |
| NCT05717920 | A Clinical Trial in Subjects With Atopic Dermatitis (Part 1) | Phase2 | Atopic Dermatitis | Completed | 2023-02-15 | 2023-11-21 | ClinicalTrials.gov |
| NCT05599815 | Part 1 - A Clinical Trial in Patients With Frequently Relapsing and Steroid-Dep… | Phase2 | Nephrotic Syndrome | Withdrawn | 2023-01-01 | 2023-05-01 | ClinicalTrials.gov |
| NCT05392179 | A Study in Subjects With Retinitis Pigmentosa | Phase2 | Retinitis Pigmentosa | Completed | 2022-07-14 | 2023-06-23 | ClinicalTrials.gov |
| NCT05392192 | A Clinical Trial to Evaluate the Safety and Efficacy in Subjects With Chronic C… | Phase2 | Chronic Cough | Completed | 2022-04-07 | 2023-04-13 | ClinicalTrials.gov |
| NCT05234554 | The INVIGORATE 2 Trial: A Clinical Trial to Assess the Efficacy and Safety of S… | Phase3 | Allergic Conjunctivitis | Completed | 2022-01-21 | 2023-04-22 | ClinicalTrials.gov |
| NCT05487404 | A Clinical Trial to Evaluate the Safety and Efficacy of ADX-629 in in Subjects … | Phase1 | Ethanol Intoxication | Completed | 2021-11-15 | 2022-05-29 | ClinicalTrials.gov |
| NCT05102409 | An Exploratory Crossover Clinical Trial to Compare the Activity of Reproxalap a… | Phase2 | Dry Eye | Completed | 2021-09-09 | 2021-10-25 | ClinicalTrials.gov |
| NCT05062330 | The TRANQUILITY 2 Trial: A Phase 3 Clinical Trial to Assess the Efficacy and Sa… | Phase3 | Dry Eye | Completed | 2021-08-28 | 2022-03-04 | ClinicalTrials.gov |
| NCT04971031 | A Clinical Trial to Assess Subjects With Dry Eye Disease. | Phase2 | Dry Eye | Completed | 2021-06-15 | 2021-09-08 | ClinicalTrials.gov |
| NCT04908514 | A Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Subjects… | Phase2 | Plaque Psoriasis | Completed | 2021-05-07 | 2022-01-21 | ClinicalTrials.gov |
| NCT04847544 | A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate the … | Phase2 | Covid19 | Completed | 2021-03-31 | 2021-10-15 | ClinicalTrials.gov |
| NCT04735393 | A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group C… | Phase3 | Dry Eye Disease | Completed | 2021-01-26 | 2022-10-11 | ClinicalTrials.gov |
| NCT04674358 | The TRANQUILITY Trial: Clinical Trial to Assess the Efficacy and Safety in Subj… | Phase2 | Dry Eye | Completed | 2020-11-21 | 2021-09-12 | ClinicalTrials.gov |
| NCT04207736 | The INVIGORATE Trial: A Clinical Trial to Assess the Efficacy and Safety of Sub… | Phase3 | Allergic Conjunctivitis | Completed | 2019-12-05 | 2021-02-16 | ClinicalTrials.gov |
| NCT03916042 | A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, … | Phase2 | Dry Eye | Completed | 2019-04-23 | 2019-11-22 | ClinicalTrials.gov |
| NCT03879863 | The RENEW Trial: A Multi-Center, Randomized, Double-Masked, Parallel-Group, Veh… | Phase3 | Dry Eye | Completed | 2019-04-16 | 2019-10-04 | ClinicalTrials.gov |
| NCT03709121 | A Methodology Development Clinical Trial of Reproxalap in Subjects With Seasona… | Phase1 | Conjunctivitis, Allergic | Completed | 2018-10-02 | 2019-03-20 | ClinicalTrials.gov |
| NCT03660878 | A Methodology Development Environmental Clinical Trial of Reproxalap in Subject… | Phase1 | Allergic Conjunctivitis | Completed | 2018-09-08 | 2019-11-19 | ClinicalTrials.gov |
| NCT03494504 | ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis | Phase3 | Allergic Conjunctivitis | Completed | 2018-03-30 | 2018-11-05 | ClinicalTrials.gov |
| NCT03404115 | A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, … | Phase2 | Dry Eye Syndrome | Completed | 2018-01-02 | 2018-07-11 | ClinicalTrials.gov |
| NCT03162783 | A Randomized, Double Masked, Clinical Study of Subjects With Dry Eye Syndrome | Phase2 | Dry Eye Syndromes | Completed | 2017-05-15 | 2017-07-06 | ClinicalTrials.gov |
| NCT03131154 | SOLACE Trial - A Phase 3 Trial in Subjects With Non-infectious Anterior-uveitis. | Phase3 | Non-infectious Anterior Uveitis | Completed | 2017-04-26 | 2019-04-26 | ClinicalTrials.gov |
| NCT03012165 | A Study of ADX-102 in Subjects With Allergic Conjunctivitis | Phase2 | Conjunctivitis, Allergic | Completed | 2016-12-01 | 2017-05-01 | ClinicalTrials.gov |
| NCT02578914 | A Safety and Activity Study of NS2 in Subjects With Allergic Conjunctivitis | Phase2 | Allergic Conjunctivitis | Completed | 2015-08-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT02406209 | A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis | Phase2 | Non-infectious Anterior Uveitis | Completed | 2015-03-01 | 2016-04-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| ADX-2191 | Other | Phase PHASE2 | Retinitis Pigmentosa | COMPLETED | NCT05392179 |
| ADX-2191 | Other | Phase PHASE2 | Retinitis Pigmentosa | COMPLETED | NCT05392179 |
| ADX-2191 | Other | Phase PHASE2 | Retinitis Pigmentosa | COMPLETED | NCT05392179 |
| ADX-2191 | Other | Phase PHASE2 | Retinitis Pigmentosa | COMPLETED | NCT05392179 |
| ADX-2191 | Other | Phase PHASE2 | Retinitis Pigmentosa | COMPLETED | NCT05392179 |
| ADX-2191 | Other | Phase PHASE2 | Retinitis Pigmentosa | COMPLETED | NCT05392179 |
| ADX-2191 | Other | Phase PHASE2 | Retinitis Pigmentosa | COMPLETED | NCT05392179 |
| Monthly ADX-2191 injection | DRUG | Phase PHASE3 | Primary Vitreoretinal Lymphoma | RECRUITING | NCT07402876 |
| ICM ADX-2191 injection | DRUG | Phase PHASE3 | Primary Vitreoretinal Lymphoma | RECRUITING | NCT07402876 |
| Vehicle ophthalmic solution | DRUG | Phase PHASE3 | Dry Eye Disease | COMPLETED | NCT06424444 |
| Reproxalap ophthalmic solution (0.25%) | DRUG | Phase PHASE3 | Dry Eye Disease | COMPLETED | NCT06424444 |
| ADX-629 (Open-label) | DRUG | Phase PHASE2 | Atopic Dermatitis | COMPLETED | NCT05717920 |
| ADX-2191 | DRUG | Phase PHASE2 | Retinitis Pigmentosa | COMPLETED | NCT05392179 |
| Xiidra® (5% lifitegrast ophthalmic solution) | DRUG | Phase PHASE2 | Dry Eye | COMPLETED | NCT05102409 |
| Placebo Comparator | DRUG | Phase PHASE3 | Dry Eye Disease | COMPLETED | NCT04735393 |
| Placebo | DRUG | Phase PHASE1 | Ethanol Intoxication | COMPLETED | NCT05487404 |
| ADX-629 | DRUG | Phase PHASE2 | Alcohol Hepatitis | COMPLETED | NCT06685692 |
| Vehicle Opthalmic Solution | DRUG | Phase PHASE2 | Dry Eye | COMPLETED | NCT04674358 |
| Standard surgical care procedure | OTHER | Phase PHASE3 | Proliferative Vitreoretinopathy | COMPLETED | NCT04136366 |
| ADX-2191 (intravitreal methotrexate 0.8%) | DRUG | Phase PHASE3 | Proliferative Vitreoretinopathy | COMPLETED | NCT04136366 |
| Vehicle Ophthalmic Solution (0.25% Novel Formulation) QID to BID | DRUG | Phase PHASE2 | Dry Eye | COMPLETED | NCT03916042 |
| Reproxalap Ophthalmic Solution (0.25% Novel Formulation) QID to BID | DRUG | Phase PHASE2 | Dry Eye | COMPLETED | NCT03916042 |
| Vehicle Ophthalmic Solution QID to BID | DRUG | Phase PHASE3 | Dry Eye | COMPLETED | NCT03879863 |
| Reproxalap Ophthalmic Solution (0.25%) QID to BID | DRUG | Phase PHASE3 | Dry Eye | COMPLETED | NCT03879863 |
| Vehicle Ophthalmic Solution QID | DRUG | Phase PHASE3 | Dry Eye | COMPLETED | NCT03879863 |
| Reproxalap Ophthalmic Solution (0.25%) QID | DRUG | Phase PHASE3 | Dry Eye | COMPLETED | NCT03879863 |
| Reproxalap Ophthalmic Solution (0.5%) | DRUG | Phase PHASE1 | Conjunctivitis, Allergic | COMPLETED | NCT03709121 |
| Vehicle of ADX-102 Topical Dermal Cream | DRUG | Phase PHASE3 | Sjogren-Larsson Syndrome | COMPLETED | NCT03445650 |
| ADX-102 1% Topical Dermal Cream (reproxalap) | DRUG | Phase PHASE3 | Sjogren-Larsson Syndrome | COMPLETED | NCT03445650 |
| Vehicle Ophthalmic Solution | DRUG | Phase PHASE3 | Dry Eye Disease | COMPLETED | NCT06493604 |
| Reproxalap Ophthalmic Solution (0.1%) | DRUG | Phase PHASE2 | Dry Eye Syndrome | COMPLETED | NCT03404115 |
| Reproxalap Ophthalmic Solution (0.25%) | DRUG | Phase PHASE3 | Dry Eye Disease | COMPLETED | NCT06493604 |
| ADX-102 Ophthalmic Lipid Solution (0.5%) | DRUG | Phase PHASE2 | Dry Eye Syndromes | COMPLETED | NCT03162783 |
| ADX-102 Ophthalmic Solution (0.1%) | DRUG | Phase PHASE2 | Dry Eye Syndromes | COMPLETED | NCT03162783 |
| Vehicle of ADX-102 Ophthalmic Solution | DRUG | Phase PHASE3 | Non-infectious Anterior Uveitis | COMPLETED | NCT03131154 |
| ADX-102 Ophthalmic Solution (0.5%) | DRUG | Phase PHASE2 | Dry Eye Syndromes | COMPLETED | NCT03162783 |
| Vehicle of ADX-102 Ophthalmic Drops | DRUG | Phase PHASE2 | Conjunctivitis, Allergic | COMPLETED | NCT03012165 |
| ADX-102 Ophthalmic Drops (0.1%) | DRUG | Phase PHASE2 | Conjunctivitis, Allergic | COMPLETED | NCT03012165 |
| ADX-102 Ophthalmic Drops (0.5%) | DRUG | Phase PHASE2 | Conjunctivitis, Allergic | COMPLETED | NCT03012165 |
| NS2 Ophthalmic Drops Vehicle (0.0%) | DRUG | Phase PHASE2 | Allergic Conjunctivitis | COMPLETED | NCT02578914 |
| NS2 Ophthalmic Drops (0.5%) | DRUG | Phase PHASE2 | Allergic Conjunctivitis | COMPLETED | NCT02578914 |
| Prednisolone acetate ophthalmic suspension (1%) | DRUG | Phase PHASE2 | Non-infectious Anterior Uveitis | COMPLETED | NCT02406209 |
| NS2 | DRUG | Phase PHASE2 | Non-infectious Anterior Uveitis | COMPLETED | NCT02406209 |
| Vehicle placebo 0.0% NS2 dermatologic cream | DRUG | Phase PHASE2 | Sjögren-Larsson Syndrome | COMPLETED | NCT02402309 |
| Active topical NS2 1% dermatologic cream | DRUG | Phase PHASE2 | Sjögren-Larsson Syndrome | COMPLETED | NCT02402309 |